Akebia Therapeutics's Return On Capital Employed Overview
Portfolio Pulse from Benzinga Insights
Akebia Therapeutics (NASDAQ:AKBA) reported Q1 sales of $40.13 million and a loss of $26.22 million. The company's Return on Capital Employed (ROCE) for Q1 was 1.83%, indicating effective capital allocation. Q1 earnings per share were $-0.14, beating analyst predictions of $-0.15.
May 22, 2023 | 2:52 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Akebia Therapeutics reported better-than-expected Q1 earnings per share and a positive ROCE of 1.83%, suggesting effective capital allocation.
Akebia Therapeutics' better-than-expected Q1 earnings per share and positive ROCE of 1.83% indicate effective capital allocation, which is a positive sign for the company's future performance. This could lead to higher returns and earnings per share growth, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100